Compare SGHC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHC | GKOS |
|---|---|---|
| Founded | 2020 | 1998 |
| Country | Guernsey | United States |
| Employees | N/A | 1094 |
| Industry | Services-Misc. Amusement & Recreation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | 2021 | 2015 |
| Metric | SGHC | GKOS |
|---|---|---|
| Price | $10.69 | $102.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $17.33 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 2.4M | 634.7K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $29.10 | $23.39 |
| Revenue Next Year | $14.20 | $27.46 |
| P/E Ratio | $20.80 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $5.59 | $73.16 |
| 52 Week High | $14.38 | $130.23 |
| Indicator | SGHC | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 52.96 | 39.00 |
| Support Level | $10.59 | $81.54 |
| Resistance Level | $11.60 | $106.52 |
| Average True Range (ATR) | 0.49 | 3.96 |
| MACD | -0.05 | -0.91 |
| Stochastic Oscillator | 36.18 | 23.74 |
Super Group (SGHC) Ltd is a holding company that operates online sports betting and gaming businesses. The company's reportable segments are Betway, Spin, and Other. A majority of its revenue is generated from the Betway segment, which is a single-brand online sports betting and casino offering with licenses to operate throughout Europe, the Americas, and Africa. Spin is the company's multi-brand online casino offering, having a diverse portfolio of casino brands such as Jackpot City, Spin Casino, Dream Bingo, Mirror Bingo, etc., designed to be culturally relevant globally while aiming to offer a wide range of casino products. Geographically, the company generates maximum revenue from Africa and Middle East, followed by North America, Europe, Asia-Pacific, and South/Latin America.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.